Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
Year: 2023
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet
Authors: Christopher W Ryan, Catherine M Tangen, Elisabeth I Heath, Mark N Stein, Maxwell V Meng, Ajjai S Alva, Sumanta K Pal, Igor Puzanov, Joseph I Clark, Toni K Choueiri, Neeraj Agarwal, Robert G Uzzo, Naomi B Haas, Timothy W Synold, Melissa Plets, Ulka N Vaishampayan, Brian M Shuch, Ian M Thompson, Primo N Lara
Institutions: Oregon Health & Science University, OHSU Knight Cancer Institute, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Columbia University, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, U-M Rogel Cancer Center, City Of Hope National Medical Center, Roswell Park Comprehensive Cancer Center, Loyola University Medical Center, Loyola University Chicago, Dana-Farber Cancer Institute, Huntsman Cancer Institute, Fox Chase Cancer Center, University of Pennsylvania, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Christus Santa Rosa Health System, UC Davis Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: U.S. Department of Defense, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, American Society of Clinical Oncology, American College of Radiology Imaging Network, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Exelixis, Celldex Therapeutics, National Comprehensive Cancer Network, Hope Foundation, ECOG-ACRIN Cancer Research Group, Castle Biosciences, Daiichi-Sankyo, Eisai, Astellas Pharma, European Society for Medical Oncology, Korea Carbon Capture and Sequestration R and D Center, Ipsen, Bavarian Nordic, National Institutes of Health, Genentech, EMD Serono, National Cancer Institute
Awards: G1065259983, G107066813, G1273380608, G1441275361, G1548551769, ECOG-ACRIN Network Group Operations Center, G1938688226, G2084874863, G2152013059, G2511164305, G2709593909, G2819266960, G2824413518, Network Lead Academic Participating Site Grant from the Roswell Park Cancer Institute, G3059322855, Yale Cancer Center NCTN LAPS, G3231584006, G3647597407, G4015574465, G4017138494, G4482309496, G4561983161, G4701663385, G5068590995, G538698522, G580335595, UNC Lead Academic Participating Site, G6396876343, G6461959565, G6536185887, G6705915398, G776903742, G792176338, Alliance for Clinical Trials in Oncology Operations Center, G9000047808, G9000097678, G9000182598, G9000189866, G9000219562, G9000293434
OpenAlex ID: W4385336354